RT Dave Ripley (@DavidLRipley)This panel hosted by the American Bankers Association said allowing companies like @krakenfx or @coinbase to pay interest on stablecoins would be “a detriment.”A detriment to who?Healthy competition is the bedrock of a free market and free markets benefit actual consumers and businesses. Consumers should have the freedom to choose where they hold value and the most efficient way to send that value.The reality is that regulatory moats do exist and they do work to enrich the comp ...

Economic Overview - China's economy faces intense competition, eroding profits [1] - This competition fosters a harsh environment for workers [1] - A deflationary spiral is being fueled [1]

Worldpay’s $24.3 billion deal with Global Payments to create a payment processing behemoth avoided a deeper investigation as the Competition and Markets Authority found the deal will not weaken competition in the UK https://t.co/3FrCk35sWN ...

Economic Overview - China's economy faces intense competition, eroding profits [1] - The competitive environment fosters a harsh rat race among workers [1] - This competition contributes to a deflationary spiral in the economy [1]

Economic Overview - China's economy faces intense competition, eroding profits [1] - The competition fosters a harsh environment for workers [1] - Deflationary pressures are intensifying within the economy [1]

whenever someone tries to compete with your business, they are implicitly saying they want your wife, children, and entire lineage's life to be worseyou should take it extremely personally and make them regret their existenceif they can sleep without crying, try again ...

The EU is fighting to salvage industries under threat from American and Chinese competitors. But the flurry of recent countermeasures may be too little, too late https://t.co/X3PFm1JMMp ...

Market Dynamics & Competition - Pharma companies are heavily investing in MASH (Metabolic dysfunction-associated steatohepatitis) drugs, indicating a significant market opportunity [1] - The entry of multiple companies into the MASH treatment space is expected to drive awareness, diagnosis, and treatment rates [3][6] - Magical Pharmaceuticals views the increasing competition as beneficial for market development, as the current penetration rate is only 7% of diagnosed patients [3][4] - The MASH market is projected to become a large specialty market, similar to rheumatoid arthritis and psoriasis markets, which are valued at over $20 billion [6][7] Magical Pharmaceuticals' Performance & Strategy - Magical Pharmaceuticals' drug Resifa (BGOI) was the first MASH drug approved by the FDA in March 2024 [1][2] - Magical Pharmaceuticals is currently on an $800 million run rate, indicating strong initial market traction [7] - The company believes it can effectively compete with larger pharmaceutical companies due to the specialized nature of the market and its targeted approach to specialists [9][10] - Magical Pharmaceuticals is tracking at or near the top of every metric compared to the 10 best specialty launches over the last 10 years [10] - The company aims to stay ahead of competitors by continuously adding tens of thousands of patients and iterating based on market experience [11]

Competition is intensifying. And with famous actors and directors advertising new premium waters, marketing doesn’t come cheap https://t.co/CJSDPzVKOy ...

Market Competition - Competition in the premium water market is intensifying [1] - Marketing costs are high due to celebrity endorsements [1]